EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)

BIOLOGICAL3 trials

Sponsors

Federal Budgetary Research Institution State Research Center of Virology and Biotechnology Vector

Conditions

COVID-19Covid19

Phase 1

Study of the Safety, Reactogenicity and Immunogenicity of EpiVacCorona Vaccine for the Prevention of COVID-19

CompletedNCT04527575

Federal Budgetary Research Institution State Research Center of Virology and Biotechnology VectorCovid19

Start: 2020-07-27End: 2021-12-30Updated: 2022-03-16

Phase 3

Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19

CompletedNCT04780035

Federal Budgetary Research Institution State Research Center of Virology and Biotechnology VectorCOVID-19

Start: 2020-11-27End: 2021-12-20Updated: 2022-03-16

Study of the EpiVacCorona Vaccine With the Involvement of Volunteers Aged 60 Years and Above

CompletedNCT05021016

Federal Budgetary Research Institution State Research Center of Virology and Biotechnology VectorCovid19

Start: 2020-11-19End: 2021-01-30Updated: 2021-08-27

Related Papers

A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II)

Russian Journal of Infection and Immunity2021-03-24109 citations